Pirenzepine (Gastrozepin), an
M1 selective antagonist, is used in the treatment of
peptic ulcers, as it reduces
gastric acid secretion and reduces
muscle spasm. It is in a class of drugs known as
muscarinic receptor antagonists;
acetylcholine is the neurotransmitter of the
parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation.[1] It has no effects on the brain and spinal cord as it cannot diffuse through the
blood–brain barrier.
Pirenzepine has been investigated for use in
myopia control.[2][3]
Pirenzepine (Gastrozepin), an
M1 selective antagonist, is used in the treatment of
peptic ulcers, as it reduces
gastric acid secretion and reduces
muscle spasm. It is in a class of drugs known as
muscarinic receptor antagonists;
acetylcholine is the neurotransmitter of the
parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation.[1] It has no effects on the brain and spinal cord as it cannot diffuse through the
blood–brain barrier.
Pirenzepine has been investigated for use in
myopia control.[2][3]